Brief by Shorts91 Newsdesk / 03:17am on 20 Jul 2025,Sunday Health & Wellness
The NHS has become the first in Europe to offer a five‑minute injectable form of nivolumab, an immunotherapy previously delivered via IV over 30–60 minutes . Approved by the MHRA, this subcutaneous jab treats 15 cancers, including lung, bowel, skin, bladder, kidney, head & neck, and oesophageal types . Around 1,200 patients per month in England are expected to benefit, saving over 1,000 staff hours monthly and boosting day-unit capacity . Clinicians report it greatly enhances patient convenience at no extra NHS cost, thanks to a deal with Bristol Myers Squibb. (PC: Survey Live)
